Presenting 17 years of experience in Healthcare sector at USA, Africa & India. Expertise acquired in Oncology, Diabetology, CNS, Cardiovascular, HIV, Nephrology & Speciality.
Currently, he is the Founder & CEO at ACE Pharma. Global clientele include:
c) Holmusk, USA
d) Myriad Genetics-USA
Prior to that he was Associate Director - Market Access at Roche Pharmaceuticals, where he developed a blue print of public health insurance model that was pivotal in implementing Arogya Bharat National Health Protection scheme in India for 50 crore people with a cover of INR 5 lakh per family. He also engaged with IRDA to initiate improvement in Private Health Insurance for Cancer in India. He implemented Patient support programs in India to improve Roche's therapy adoption and adherence, and also contributed to Annual marketing plan for key brands in oncology (Avastin and Tecentriq) and Specialty (Actemra and Mircera).
Prior to it he was Associate Director - Business Development and Marketing at Dr. Reddy's Labs, where he was heading business development for the North Africa region (Algeria, Morocco, Egypt, and Tunisia). He designed and executed market entry strategy, partner selection, contract negotiation, product registration, budget, and won a army tender in Algeria for $2million. He also engaged with the government to expedite product registration, plant audit, and approvals to launch sooner in North African countries. Peak sales estimate of USD 80 million. Additionally, he headed BD for South Africa to in-license drugs with peak sales of $20 mn in CNS, CV, pain, and critical care, including their ideation, business case, and contracts.
Prior to it he was Financial Controller for global institution business at Cipla, where he was key contributor in M&As at Middle East & Africa: Acquired majority stake in Uganda's QCIL, and in Iran's Ahran Pharma. He also aided in scouting & negotiating to appoint Business partners & Distributors in Kenya. He identified the opportunity for third generation therapy products in the HIV portfolio, and successfully negotiated the in-licensing contract with Merck for Raltegravir. He was also the alliance manager for DNDi (a United Nations body) to develop pediatric ARV formulations. In addition, he oversaw pricing strategy and analytics to big global fund tenders for anti-malaria and ARVs.
Prior, he was Global Business Development & Marketing Manager at Biocon Ltd. for biosimilar Insulin & analogs. Key commercial driver for Biocon-Mylan alliance.
CEO, ACE Pharma
MS, MBA (both from top schools in USA)
[Ex-Roche, Cipla, Biocon & Dr. Reddy's Labs]